News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novartis AG’s Drug Onbrez Breezhaler Proved More Effective Against COPD than Other Drugs
September 20, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Novartis' lung drug Onbrez Breezhaler allows patients with a deadly lung disease to breathe more easily than a current mainstay treatment, adding to positive sentiment surrounding the Swiss drugmaker.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Novartis
MORE ON THIS TOPIC
Neuroscience
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial
December 23, 2025
·
2 min read
·
Nick Paul Taylor
Clinical research
Pfizer Reports Patient Death in Long-Term Trial of Hympavzi for Hemophilia A
December 23, 2025
·
1 min read
·
Annalee Armstrong
Lung cancer
AstraZeneca’s ATR Inhibitor Fails To Improve Survival in Phase III Lung Cancer Trial
December 22, 2025
·
1 min read
·
Annalee Armstrong
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
December 22, 2025
·
1 min read
·
Annalee Armstrong
